Ignite Creation Date:
2025-12-25 @ 2:29 AM
Ignite Modification Date:
2026-01-22 @ 6:15 AM
Study NCT ID:
NCT04153734
Status:
NOT_YET_RECRUITING
Last Update Posted:
2019-11-06
First Post:
2019-10-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
Sponsor:
Kobe Minimally Invasive Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-12-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2021-11-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-11-30
Completion Date Type:
ESTIMATED
First Submit Date:
2019-10-28
First Submit QC Date:
None
Study First Post Date:
2019-11-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-11-05
Last Update Post Date:
2019-11-06
Last Update Post Date Type:
ACTUAL